Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of linperlisib + camrelizumab + CHOP in newly diagnosed PTCL ineligible for AHSCT
ChiCTR2300072644Phase 2Recruiting
- Sponsor
- Shengli Oilfield Central Hospital
- Start
- Jun 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of linperlisib, camrelizumab, cyclophosphamide, doxorubicin, vincristine and 1 more in peripheral T-cell lymphoma (PTCL), sponsored by Shengli Oilfield Central Hospital. Primary endpoints: Overall response rate and Complete response rate. Started Jun 2023; status: recruiting.
02
Drugs
linperlisibcamrelizumabcyclophosphamidedoxorubicinvincristine
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2300072644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072644.